Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
39414159
DOI
10.1053/j.gastro.2024.10.010
PII: S0016-5085(24)05572-0
Knihovny.cz E-resources
- Keywords
- Fibroscan, Lung Emphysema, SERPINA1,
- MeSH
- alpha 1-Antitrypsin * genetics MeSH
- Aspartate Aminotransferases blood MeSH
- alpha 1-Antitrypsin Deficiency * genetics mortality complications diagnosis MeSH
- Adult MeSH
- Elasticity Imaging Techniques MeSH
- Genotype MeSH
- Homozygote MeSH
- Liver Cirrhosis * genetics mortality diagnosis etiology blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Mutation MeSH
- Disease Progression MeSH
- Aged MeSH
- Severity of Illness Index MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Names of Substances
- alpha 1-Antitrypsin * MeSH
- Aspartate Aminotransferases MeSH
- SERPINA1 protein, human MeSH Browser
BACKGROUND & AIMS: Homozygous Pi∗Z mutation in alpha-1 antitrypsin (Pi∗ZZ genotype) predisposes to pulmonary loss-of-function and hepatic gain-of-function injury. To facilitate selection into clinical trials typically targeting only 1 organ, we systematically evaluated an international, multicenter, longitudinal, Pi∗ZZ cohort to uncover natural disease course and surrogates for future liver- and lung-related endpoints. METHODS: Cohort 1 recruited 737 Pi∗ZZ individuals from 25 different centers without known liver comorbidities who received a baseline clinical and laboratory assessment as well as liver stiffness measurement (LSM). A follow-up interview was performed after at least 6 months. Cohort 2 consisted of 135 Pi∗ZZ subjects without significant liver fibrosis, who received a standardized baseline and follow-up examination at least 2 years later, both including LSM. RESULTS: During 2634 patient-years of follow-up, 39 individuals died, with liver and lung being responsible for 46% and 36% of deaths, respectively. Forty-one Pi∗ZZ subjects who developed a hepatic endpoint presented with significantly higher baseline liver fibrosis surrogates, that is, LSM (24 vs 5 kPa, P < .001) and aspartate aminotransferase-to-platelet ratio index (1.1 vs 0.3 units, P < .001). Liver-related endpoints within 5 years were most accurately predicted by LSM (area under the curve 0.95) followed by aspartate aminotransferase-to-platelet ratio index (0.92). Baseline lung parameters displayed only a moderate predictive utility for lung-related endpoints within 5 years (forced expiratory volume in the first second area under the curve 0.76). Fibrosis progression in those with no/mild fibrosis at baseline was rare and primarily seen in those with preexisting risk factors. CONCLUSIONS: Noninvasive liver fibrosis surrogates accurately stratify liver-related risks in Pi∗ZZ individuals. Our findings have direct implications for routine care and future clinical trials of Pi∗ZZ patients.
1st Department of Medicine Paracelsus Medical University Salzburg Salzburg Austria
AP HP service d'hépatologie Hôpital Beaujon AP HP Clichy France DMU Digest Clichy France
Department of Internal Medicine 1 Medical University Innsbruck Innsbruck Austria
Department of Pulmonology Leiden University Medical Center Leiden The Netherlands
Division of Gastroenterology Hepatology and Nutrition University of Florida Gainesville Florida
Division of Hepatology Department of Medicine Leipzig University Medical Center Leipzig Germany
Institute of Applied Health Research University of Birmingham Birmingham United Kingdom
Institute of Liver Studies King's College Hospital NHS Foundation Trust London United Kingdom
References provided by Crossref.org